Program
recombinant FVIIa
Also written as “activated recombinant human factor VII”, “eptacog alfa (activated)” and “Coagulation Factor VIIa (Recombinant)”.
Its studies are mostly in Hemophilia A · Cerebral Hemorrhage · Wounds and Injuries · Fibrosis · Postpartum Hemorrhage, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 361 open or running | phase 4since Dec 11, 2007 | Jan 19, 2005 | Aug 26, 2027phase 4 · NCT07157423 |
| Laboratoire français de Fractionnement et de Biotechnologies | 20 open or running | phase 3since Sep 9, 2015 | Sep 9, 2015 | none ahead |
| rEVO Biologics | 20 open or running | phase 3since Dec 18, 2013 | Oct 15, 2012 | none ahead |
| AryoGen Pharmed | 10 open or running | phase 3since Mar 4, 2017 | Mar 4, 2017 | none ahead |
Also a collaborator on its studies: LFB USA.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 13 studies since Jan 19, 2005.
- Jul 8, 2011Phase 3 study in Congenital Bleeding DisorderNovo Nordisk · NCT01392547 · 72 enrolled · United States, Austria, Brazil and more
- Mar 21, 20127 phase 1 studiesNovo Nordisk · NCT01562457, NCT01561950, NCT01561937 and 4 more
- Mar 21, 2012Phase 4 study in Congenital Bleeding DisorderNovo Nordisk · NCT01561391 · 36 enrolled · United States
- Mar 21, 20128 phase 2 studiesNovo Nordisk · NCT01561352, NCT01563458, NCT01562821 and 5 more
- Mar 22, 2012Phase 3 study in Acquired Bleeding DisorderNovo Nordisk · NCT01562574 · 82 enrolled · Australia
- May 14, 20122 phase 2 studiesNovo Nordisk · NCT01601613, NCT01601457
- Oct 15, 2012rEVO Biologics’ first study: phase 1 study in Hemophilia ANew to rEVO BiologicsrEVO Biologics · NCT01708564 · 15 enrolled · United States, Netherlands
- Sep 13, 2013Phase 1 study in Hemophilia ANovo Nordisk · NCT01949792 · 6 enrolled · Spain
- Dec 18, 2013Phase 3 study in Hemophilia A With InhibitorsrEVO Biologics · NCT02020369 · 27 enrolled · United States, Belarus, Bulgaria and more
- Jan 28, 2014Phase 1 study in Hemophilia ANovo Nordisk · NCT02084810
- Sep 9, 2015Laboratoire français de Fractionnement et de Biotechnologies’ first study: phase 3 study in Hemophilia ANew to Laboratoire français de Fractionnement et de BiotechnologiesLaboratoire français de Fractionnement et de Biotechnologies · NCT02548143 · 12 enrolled · United States, Mexico, Russian Federation and more
- Mar 4, 2017AryoGen Pharmed’s first study: phase 3 study in Factor VII DeficiencyNew to AryoGen PharmedAryoGen Pharmed · NCT03079063 · 24 enrolled · Iran, Islamic Republic of
- Dec 21, 2022Phase 3 study in Hemophilia ALaboratoire français de Fractionnement et de Biotechnologies · NCT05695391 · 2 enrolled · United States, Malaysia, Mexico and more
- Aug 19, 2025Phase 4 study in Postpartum HemorrhageNovo Nordisk · NCT07157423 · 64 planned · India
Ahead
- Aug 26, 2027Primary completion: phase 4 study in Postpartum HemorrhageNovo Nordisk · NCT07157423
TargetBeta
“A recombinant form of the vitamin K-dependent glycoprotein and coagulation factor VIIa (FVIIa), that can be used for the treatment of bleeding episodes and perioperative management in patients with hemophilia, congenital Factor VII (FVII) deficiency, and Glanzmann's thrombasthenia”NCIt, by rule
Studies
All 41 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07157423Postpartum Hemorrhage · India | 4 | Recruiting | Novo Nordisk | Aug 26, 2027 | 64 |
| NCT05695391Hemophilia A · United States, Malaysia, Mexico and more | 3 | Terminated | Laboratoire français de Fractionnement et de Biotechnologies | May 28, 2025 | 2 |
| NCT03079063Factor VII Deficiency · Iran, Islamic Republic of | 3 | Completed | AryoGen Pharmed | Nov 30, 2020 | 24 |
| NCT02548143Hemophilia A · United States, Mexico, Russian Federation and more | 3 | Completed | Laboratoire français de Fractionnement et de Biotechnologies | Aug 6, 2017 | 12 |
| NCT02084810Hemophilia A | 1 | Withdrawn | Novo Nordisk | Jul 2014 | 0 |
| NCT02020369Hemophilia A With Inhibitors · United States, Belarus, Bulgaria and more | 3 | Completed | rEVO Biologics | Jul 2015 | 27 |
| NCT01949792Hemophilia A · Spain | 1 | Completed | Novo Nordisk | Nov 2013 | 6 |
| NCT01708564Hemophilia A · United States, Netherlands | 1 | Completed | rEVO Biologics | Jun 2013 | 15 |
| NCT01601457Wounds and Injuries · United Kingdom | 2 | Completed | Novo Nordisk | Apr 2004 | 48 |
| NCT01601613Dengue · Malaysia, Philippines, Thailand | 2 | Completed | Novo Nordisk | Nov 2002 | 28 |
| NCT01566786Cerebral Hemorrhage · Australia, Denmark, Finland and more | 2 | Completed | Novo Nordisk | Oct 2002 | 48 |
| NCT01564563Acquired Bleeding Disorder · United States | 2 | Terminated | Novo Nordisk | Oct 27, 2003 | 11 |
| NCT01563523Wounds and Injuries · Australia, Austria, Canada and more | 2 | Completed | Novo Nordisk | Oct 2003 | 283 |
| NCT01563471Congenital Bleeding Disorder · France | 1 | Completed | Novo Nordisk | Jul 2002 | 39 |
| NCT01563445Cerebral Hemorrhage · United States | 2 | Completed | Novo Nordisk | Mar 2003 | 40 |
| NCT01563458Acquired Bleeding Disorder · Australia, Canada, France and more | 2 | Completed | Novo Nordisk | Aug 2003 | 208 |
| NCT01562821Fibrosis · China, Taiwan, Thailand | 2 | Completed | Novo Nordisk | Dec 2002 | 235 |
| NCT01562587Hemophilia A · Germany, Greece, Italy and more | 1 | Completed | Novo Nordisk | May 2003 | 18 |
| NCT01562574Acquired Bleeding Disorder · Australia | 3 | Completed | Novo Nordisk | Aug 2004 | 82 |
| NCT01562158Acquired Bleeding Disorder · United States, Australia, Austria and more | 2 | Completed | Novo Nordisk | Oct 2003 | 100 |
| NCT01562457Hemophilia A · France, Germany, Israel | 1 | Completed | Novo Nordisk | Apr 2006 | 30 |
| NCT01561950Haemostasis · United States | 1 | Terminated | Novo Nordisk | Jan 2009 | 91 |
| NCT01561937Haemostasis · United States | 1 | Completed | Novo Nordisk | Jul 2008 | 127 |
| NCT01561924Congenital Bleeding Disorder · United States, Denmark, France and more | 1 | Completed | Novo Nordisk | May 2006 | 17 |
| NCT01561417Thrombasthenia · France | 1 | Completed | Novo Nordisk | Sep 2006 | 28 |
| NCT01561391Congenital Bleeding Disorder · United States | 4 | Completed | Novo Nordisk | May 2004 | 36 |
| NCT01561352Cystitis, Hemorrhagic · United States | 2 | Completed | Novo Nordisk | Nov 2003 | 7 |
| NCT01392547Congenital Bleeding Disorder · United States, Austria, Brazil and more | 3 | Completed | Novo Nordisk | Aug 2012 | 72 |
| NCT00571584Congenital Bleeding Disorder · France, Hungary, Israel and more | 4 | Completed | Novo Nordisk | Mar 2004 | 24 |
| NCT00486278Hemophilia A · United States, Argentina, Brazil and more | 2 | Completed | Novo Nordisk | Jun 2010 | 51 |
| NCT00426803Cerebral Hemorrhage · Australia, Austria, Belgium and more | 2 | Completed | Novo Nordisk | Jun 2004 | 400 |
| NCT00323570Wounds and Injuries · United States | 3 | Withdrawn | Novo Nordisk | Jun 2007 | 0 |
| NCT00266006Cerebral Hemorrhage · Japan | 2 | Completed | Novo Nordisk | Apr 2007 | 90 |
| NCT00184548Wounds and Injuries · United States, Brazil, Czech Republic and more | 3 | Terminated | Novo Nordisk | Sep 2008 | 554 |
| NCT00154492Fibrosis · Austria, Czech Republic, Denmark and more | 2 | Completed | Novo Nordisk | Aug 2006 | 265 |
| NCT00154427Acquired Bleeding Disorder · United States, Argentina, Brazil and more | 2 | Terminated | Novo Nordisk | Nov 2007 | 172 |
| NCT00127283Cerebral Hemorrhage · United States, Australia, Austria and more | 3 | Completed | Novo Nordisk | Jan 2007 | 829 |
| NCT00123591Wounds and Injuries · Canada, Finland, Germany and more | 2 | Completed | Novo Nordisk | May 2006 | 96 |
| NCT00108758Congenital Bleeding Disorder · United States, Argentina, Brazil and more | 2 | Completed | Novo Nordisk | Nov 2005 | 23 |
| NCT00104455Congenital Bleeding Disorder · United States | 1 | Completed | Novo Nordisk | Nov 2004 | 64 |
| NCT00102037Acquired Bleeding Disorder · United States | 2 | Completed | Novo Nordisk | Feb 2006 | 50 |
How it is read
Names in the registry
- “activated recombinant human factor VII”, 32 entries
- “eptacog alfa (activated)”, 12 entries
- “Coagulation Factor VIIa (Recombinant)”, 3 entries
- “Eptacog alfa (NovoSeven)”, 1 entry
- “Eptacog alfa, biosimilar”, 1 entry
Conditions, from the studies’ own filings
- Hemophilia A, 15 studies
- Cerebral Hemorrhage, 5 studies
- Wounds and Injuries, 5 studies
- Fibrosis, 2 studies
- Postpartum Hemorrhage, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.